Paroxysmal Atrial Tachycardia Market Information: by Type (AV Nodal Re-Entrant Tachycardia (AVNRT), AV Reciprocating Tachycardia (AVRT)), Diagnosis (ECG, Echocardiogram) Treatment (Calcium Channel Blockers, Digoxin), End User - Global forecast till 2023

Market Synopsis of Global Paroxysmal Atrial Tachycardia Market

Market Scenario

Paroxysmal atrial tachycardia is irregular heartbeat and is a type of atrial arrhythmia where the episode of arrhythmia begins and ends abruptly. Paroxysmal atrial tachycardia (PAT) is also known as paroxysmal supraventricular tachycardia (PSVT). PAT increases heart rate from 60 to 100 beats per minute (bpm) to between 130 and 230 bpm with infants demonstrating heart rate greater than 220 bpm. PAT is the most common form of tachycardia in infants and children. Symptoms of PAT may include palpitations, lightheadedness, sweating, shortness of breath, chest pain and others. PAT is not usually a life-threatening disorder and the symptoms subside on their own. However, in rare cases, PAT may cause unconsciousness, congestive heart failure, cardiomyopathy and cardiac arrest. Having other heart issues such heart attacks or valve disease increase risk for PAT.

The cause of PAT are unknown but risk factors include alcohol, caffeine, nicotine, psychological stress, and Wolff-Parkinson-White syndrome. PAT occurs when electrical signals starting in the heart’s atria fire irregularly which affects the electrical signals transmitted from the sinoatrial node. This irregular beating prevents your heart from having enough time to fill with blood before pumping blood resulting in the body not receiving enough blood or oxygen. Women are at a higher risk for PAT than men.

The market drivers for global paroxysmal atrial tachycardia market are rise in demand due to growing older population, increasing screening, greater emphasis on cardiac treatment, urgency of the paroxysmal atrial tachycardia treatment, rise in risk factors and others. The market restraints are the complications such as risk of bleeding, infections, pain, especially during surgery, high cost of paroxysmal atrial tachycardia treatment, lack of cardiac care infrastructure, and lack of focus on other diseases by the developing regions and others.

The global paroxysmal atrial tachycardia market is expected to reach USD 10.7 billion by 2023, and the market is projected to grow at a CAGR of ~ 6.5 % during the forecast period 2017-2023.

Research Methodology
Intended Audience

- Global Paroxysmal Atrial Tachycardia manufacturers & suppliers
- Research and development (R&D) companies
- Hospitals and clinics
- Academic institutes and universities

Figure 1  Global Paroxysmal Atrial Tachycardia Market by Treatment, 2016 (%)

Segments
The global paroxysmal atrial tachycardia market has been segmented on the basis of types, condition, diagnosis, drugs, surgery and end user.

Based on the types, the market has been segmented as AV nodal re-entrant tachycardia (AVNRT), AV reciprocating tachycardia (AVRT), and paroxysmal atrial tachycardia.
Based on the diagnosis, the market has been segmented as electrocardiogram (ECG), echocardiogram, blood tests, and electrophysiology study (EPS) and others.

Based on the treatment, the market has been segmented as calcium channel blockers, digoxin, beta-blockers, anti-arrhythmic medications, surgical ablation and others.

Based on the end user, the market has been segmented as hospitals and clinics, research and academics and others.

Regional Analysis
The Americas account for a significant market share owing to high expenditure on the health care especially in the U.S. and Canada. Additionally, the greater number of cardiac procedures due to greater healthcare penetration in the U.S. and Canada drives the paroxysmal atrial tachycardia market. The high concentration of the major hospitals in the developed countries of this region coupled with good reimbursement rates is also adding fuel to the market growth. Moreover, the large share of cardiac procedures especially the cardiac surgery treatment in the returns of hospitals favors the market. The large number of pharmaceutical companies in the U.S. is also a cause for the faster development of paroxysmal atrial tachycardia market in the U.S. The high development of microsurgery field in developed regions such as the U.S. and Europe is a strong driver of the market.

Europe is the second largest market in the world due to growing pharmaceutical industry and healthcare penetration. The European market growth is led by countries such as Germany and France. Germany is expected to be the fastest growing market over the assessment period due to its large pharmaceutical and microsurgery devices industry.

Asia Pacific region is expected to grow rapidly; China and India are likely to lead this market due to the fast growing healthcare sector and large unmet needs over the forecast period. South East Asian countries such as China, India, and Malaysia are projected to contribute highly to the market growth. The growing penetration of healthcare industry in the Asia Pacific region is expected to drive the future paroxysmal atrial tachycardia market in the region. However the low expenditure on cardiac and eye care coupled with the lack of insurance penetration in the developing regions is a dent on the market.

Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for are Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a poor growth owing to poor economic and political conditions, and poor healthcare development. Other regions are expected to be laggards due to poor social development and tribal identities such as sub Saharan Africa. The focus of the governments of poor countries on fulfilling basic healthcare relegates the paroxysmal atrial tachycardia market to the background which hampers the development of the market.

Key Players in the Global Paroxysmal Atrial Tachycardia Market

Contents:
Table of Content
1. Report Prologue
2. Market Introduction
   2.1 Definition
   2.2 Scope of the Study
   2.2.1 Research Objective
   2.2.2 Assumptions
   2.2.3 Limitations
3. Research Methodology
   3.1 Introduction
   3.2 Primary Research
   3.3 Secondary research
   3.4 Market Size Estimation
4. Market Dynamics
9.2.1 Market Estimates & Forecast, 2011-2023

9.3 Research and Academics

9.3.1 Market Estimates & Forecast, 2011-2023

9.4 Others

9.4.1 Market Estimates & Forecast, 2011-2023

10. Global Paroxysmal Atrial Tachycardia Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 US

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 UK

10.3.1.4 Italy

10.3.1.5 Spain

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

11. Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

12. Company Profiles

12.1 Abbott Laboratories

12.1.1 Overview

12.1.2 Product Overview

12.1.3 Financials

12.1.4 Key

12.2 Reliant Pharmaceuticals C

12.2.1 Overview
12.2.2 Product Overview
12.2.3 Financials
12.2.4 Key Developments
12.3 Novartis AG
12.3.1 Overview
12.3.2 Product Overview
12.3.3 Financials
12.3.4 Key Development
12.4 AstraZeneca PLC
12.4.1 Overview
12.4.2 Product Overview
12.4.3 Financials
12.4.4 Key Development
12.5 BIOTRONIK SE & Co. KG
12.5.1 Overview
12.5.2 Product Overview
12.5.3 Financials
12.5.4 Key Development
12.6 Teva pharmaceutical industries
12.6.1 Overview
12.6.2 Product Overview
12.6.3 Financials
12.6.4 Key Development
12.7 Boston Scientific Corporation
12.7.1 Overview
12.7.2 Product Overview
12.7.3 Financials
12.7.4 Key Development
12.8 Glenmark Pharmaceuticals
12.8.1 Overview
12.8.2 Product Overview
12.8.3 Financials
12.8.4 Key Development
12.9 Koninklijke Philips N.V.
12.9.1 Overview
12.9.2 Product Overview
12.9.3 Financials
12.9.4 Key Development

13. MRFR Conclusion
13.1 Key Findings
13.1.1 From CEO’s View Point
13.1.2 Unmet Needs of the Market
13.2 Key Companies to Watch
13.3 Prediction of Paroxysmal Atrial Tachycardia Treatment Industry

14. Appendix

List of Tables

TABLE 1 GLOBAL PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY TYPES, 2017-2023 (USD MILLION)
TABLE 2 AV NODAL RE-ENTRANT TACHYCARDIA (AVNRT) FOR PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY REGION, 2017-2023 (USD MILLION)

TABLE 3 AV RECIPROCATING TACHYCARDIA (AVRT) FOR PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY REGION 2017-2023 (USD MILLION)

TABLE 4 PAROXYSMAL ATRIAL TACHYCARDIA FOR PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY REGION 2017-2023 (USD MILLION)

TABLE 5 GLOBAL PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY DIAGNOSIS, 2017-2023 (USD MILLION)

TABLE 6 ELECTROCARDIOGRAM (ECG) FOR PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY REGION, 2017-2023 (USD MILLION)

TABLE 7 ECHOCARDIOGRAM FOR PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY REGION 2017-2023 (USD MILLION)

TABLE 8 BLOOD TESTS FOR PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY REGION 2017-2023 (USD MILLION)

TABLE 9 ELECTROPHYSIOLOGY STUDY (EPS) FOR PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY REGION 2017-2023 (USD MILLION)

TABLE 10 OTHERS FOR PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY REGION 2017-2023 (USD MILLION)

TABLE 11 GLOBAL PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY TREATMENT, 2017-2023 (USD MILLION)

TABLE 12 CALCIUM CHANNEL BLOCKERS FOR PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY REGION, 2017-2023 (USD MILLION)

TABLE 13 DIGOXIN FOR PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY REGION 2017-2023 (USD MILLION)

TABLE 14 BETA BLOCKERS FOR PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY REGION 2017-2023 (USD MILLION)

TABLE 15 ANTI-ARRHYTHMIC MEDICATIONS FOR PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY REGION 2017-2023 (USD MILLION)

TABLE 16 SURGICAL ABLATION FOR PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY REGION 2017-2023 (USD MILLION)

TABLE 17 OTHERS FOR PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY REGION 2017-2023 (USD MILLION)

TABLE 18 GLOBAL PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY END USER, 2017-2023 (USD MILLION)

TABLE 19 NORTH AMERICA PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY COUNTRY 2017-2023 (USD MILLION)

TABLE 20 NORTH AMERICA PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY TYPES 2017-2023 (USD MILLION)

TABLE 21 NORTH AMERICA PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY DIAGNOSIS 2017-2023 (USD MILLION)

TABLE 22 NORTH AMERICA PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY TREATMENT 2017-2023 (USD MILLION)

TABLE 23 NORTH AMERICA PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY END USER, 2017-2023 (USD MILLION)

TABLE 24 NORTH AMERICA PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY REGION 2017-2023 (USD MILLION)

TABLE 25 EUROPE PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY COUNTRY 2017-2023 (USD MILLION)

TABLE 26 EUROPE PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY TYPES 2017-2023 (USD MILLION)

TABLE 27 EUROPE PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY DIAGNOSIS 2017-2023 (USD MILLION)

TABLE 28 EUROPE PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY TREATMENT 2017-2023 (USD MILLION)

TABLE 29 EUROPE PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY END USER, 2017-2023 (USD MILLION)

TABLE 30 ASIA PACIFIC PAROXYSMAL ATRIAL TACHYCARDIA MARKET BY REGION 2017-2023 (USD MILLION)

TABLE 31 ASIA PACIFIC PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY TYPES 2017-2023 (USD MILLION)

TABLE 32 ASIA PACIFIC PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY DIAGNOSIS 2017-2023 (USD MILLION)

TABLE 33 ASIA PACIFIC PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY TREATMENT 2017-2023 (USD MILLION)